麻豆传媒

Dr. Manz graduated from Duke University School of Medicine in 2012. He received his training in internal medicine at the Hospital of the University of Pennsylvania from 2012-2015, and subsequently worked as a hospitalist in oncology at the same hospital until 2017. After completing fellowship in hematology/oncology and a Masters of Science in Health Policy Research at the University of Pennsylvania, he joined Dana-Farber in GI Oncology and the Department of Population Sciences 2020.

Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.




 

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children's Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron's current work focuses on patient, parent and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

Dr. Gillani uses computational techniques to understand the markers in cancer and normal patient genomes that are associated with the development and progression of disease, leveraging these insights to inform novel approaches to the treatment of pediatric cancer. He cares for patients with a range of solid tumor and hematologic malignancy diagnoses, with the overall aim of translating research insights to improved patient management.




 

Cheryl London, D.V.M., Ph.D., ACVIM, is the Anne Engen and Dusty Professor of Comparative Oncology and associate dean for research and graduate education at Cummings School of Veterinary Medicine. London joined Tufts in 2016. She is director of Clinical Research Shared Resource, which oversees studies in client-owned animals at Cummings School.
London oversees the Research Collaboration Team at the Tufts Clinical Translational Science Institute, working to catalyze broadly engaged team science. She is a research professor at the School of Medicine and is a member of the Immunology Graduate Program at the Graduate School of Biomedical Sciences. London has ongoing collaborations with the Broad Institute, UMass Chan Medical School, Tufts Medical Center, MIT, and Tufts School of Medicine, as well as several projects with industry partners. These include immuno-oncology studies in the setting of osteosarcoma, and diffuse large B cell lymphoma and soft tissue sarcoma that involve spontaneous cancer in dogs to study novel strategies aimed at altering the tumor microenvironment and utilizing unique small molecule/immunotherapy combinations.
London earned her D.V.M. at Cummings School, completed her residency in medical oncology at the University of Wisconsin-Madison, and received her Ph.D. in immunology at Harvard University, where she was also a postdoctoral fellow in the Department of Pathology. Prior to joining Cummings School London was the Shackelford Professor at The Ohio State University’s College of Veterinary Medicine and assistant professor at the University of California, Davis School of Veterinary Medicine.

Daniel King, MD, PhD, is a former Howard Hughes research scholar at the National Institutes of Health and trained in genomics and bioinformatics at the Wellcome Trust Sanger Institute, where he developed software tools to perform mosaic copy number detection. During his time at the Wellcome Trust Sanger Institute, he spearheaded copy number analysis for 36,000 exome samples in the Deciphering Developmental Disorder Rare Disease project. The results from this work characterized unprecedented detail in the landscape and architecture of developmental disorders, was published in Nature and Lancet, and led to several first author publications.
Following medical and graduate school, Dr. King pursued a medical oncology fellowship under the ABIM Research Track pathway at Stanford University. A core focus of his fellowship research involved circulating tumor DNA (ctDNA), which included the computational design of a ctDNA detection panel for pancreas cancer and laboratory validation. This work extended to fragmentomics—a computational analysis of circulating DNA fragment ends as a biomarker of cancer for early detection. From here, Dr. King created a large biobank of pancreas cancer specimens consisting of nearly 500 clinical blood samples from approximately 250 patients. He went on to link this biobank with a large clinical research database built in pancreatic cancer to mine and associate clinical data with translational correlates.

Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at the Keck School of Medicine of the University of Southern California. He is currently associate professor of clinical medicine in the Division of Medical Oncology, a member of the Gastrointestinal Cancers Program and director of the phase I drug development clinical program. He has been the medical director of the Clinical Investigations Support Office at the USC Norris Comprehensive Cancer Center since 2007.
His primary research interests include the development of novel drugs for the treatment of solid tumors, especially gastrointestinal malignancies, the design and conduct of phase I and II clinical trials to test these drugs, and translational research focused on developing prognostic and predictive markers in patients with GI malignancies. Dr. El-Khoueiry has established a national reputation in the area of hepatobiliary cancers clinical research; he is the co-chair of the hepatobiliary cancers committee of the Southwest Oncology Group (SWOG) and a member of the National Cancer Institute (NCI) hepatobiliary cancers task force. He is the principal investigator on several clinical trials that are evaluating the role of novel drugs for the treatment of biliary and hepatocellular cancers.
As the phase I program director, Dr. El-Khoueiry has formed an experienced and highly skilled phase I clinical research team and established an efficient infrastructure for the conduct of high quality and innovative phase I studies. He has also worked with basic scientists at the USC Norris Comprehensive Cancer Center to design phase I studies to test novel compounds or novel combinations that had undergone pre-clinical testing at USC.
Dr. El-Khoueiry is frequently invited to give lectures nationally about gastrointestinal malignancies, particularly hepatobiliary cancers, and has a large number of peer-reviewed publications in his areas of research.

---

---

Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Merchan is a tenured Professor of Medicine in the division of Medical Oncology. He is the Co-leader of the Translational and Clinical Oncology Research Program, the Director of the Phase 1 Clinical Trials Program, and the Associate Director of the NIH funded Calabresi Clinical Oncology Research Career Development Award. As a physician scientist, his contributions to science include redefining the role of the plasminogen activator system in cancer progression, the development of novel preclinical and clinical strategies to overcome resistance in RCC and angiogenesis dependent cancers, and the preclinical and clinical development of tumor and stromal targeted oncolytic viruses and virus-drug combinations. He leads the only academic phase I program in South Florida, bringing novel treatment strategies to many patients with advanced cancer. Dr. Merchan has an established track record in translational cancer research, bringing lab discoveries to the clinic, and has been involved in the development of novel, effective treatment strategies in genitourinary cancers, which resulted in practice changing publications and introduced new treatment options for cancer patients.

Dr. Andrei Nikiforchin is a dedicated surgical oncologist, who graduated from the First Pavlov State Medical University in St. Petersburg, Russia, and further trained across Europe and the United States. He has distinguished himself in various roles, including a Clinical Researcher in Surgical Oncology at Mercy Medical Center in Baltimore, MD, a Medical Writer and Editor at "OncoWiki", and an Expert Consultant at "Prosto Sprosit'". Renowned for his surgical expertise and significant contributions to oncology research, Dr. Nikiforchin has authored multiple peer-reviewed publications. His experience is further amplified by his active participation in various professional consortiums and societies, commitment to community-oriented initiatives, and proficiency in English, Ukrainian, and Russian.
Andrei Nikiforchin, M.D., is a GCP-certified researcher in the Surgical Oncology Department of The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland, USA. He received his medical doctor degree at Pavlov First State Medical University in St. Petersburg, Russia, in 2015, and then got two specialties in general surgery and surgical oncology. In 2018 after finishing his work in Clinical Hospital #1 MEDSI in Moscow, Russia, Dr. Nikiforchin moved to the United States and started research at The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland. His areas of interest and investigation include gastrointestinal and neuroendocrine tumors, peritoneal surface malignancies, and cytoreductive surgery. Dr. Andrei Nikiforchin is a member of ASCO and SSO since 2019 and RUSSCO since 2021.

Bailey Loving, originally from Denver, Colorado, embarked on his academic journey in molecular biology at The University of Denver, where he developed an early interest in radiation biology. He then completed his medical doctorate at the University of Colorado, where he further pursued his interest in oncology. Currently training at Beaumont, Bailey is dedicated to enhancing his skills in using diverse radiation modalities for complex cases and is keen on integrating basic science research with clinical applications. Outside of his professional endeavors, he enjoys wildlife photography, canoeing in the Great Lakes, spending time with his fiancé, playing the piano, playing video games, and continually learning new things. Additionally, Bailey takes pleasure in coding, wildlife photography (Instagram @drlovingphotography), playing with his mini Goldendoodle, Guinea, and playing ping pong.

---

Dr. Gupta is a genitourinary oncologist with a research focus on clinical and translational research in genitourinary cancers. Prior to joining the Cleveland Clinic in June 2019, Dr. Gupta was an associate professor at the University of Minnesota where she led the phase I interdisciplinary Solid Tumor Program and Genitourinary Oncology Research. 



Research Information

Research Interests

Dr. Gupta has expertise and interest in novel targeted therapy and immunotherapy trials across genitourinary cancers. She has led several early and late-phase clinical trials including investigator-initiated trials with novel combinations in bladder cancer and testicular cancer, for example, neoadjuvant use of nivolumab and platinum doublet in muscle-invasive bladder cancer, enzalutamide and platinum-doublet in metastatic androgen receptor-positive bladder cancer, brentuximab and bevacizumab in CD30+ germ cell tumors. In collaboration with her basic science colleagues including Dr. Scott Dehm at University of Minnesota, she is studying the molecular efficacy of enzalutamide.
Dr. Gupta is also interested in understanding the resistance mechanisms to anti-PD-1/PD-L1 therapies and serves as a member of the Society for Immunotherapy of Cancer Anti-PD-1/PD-L1 resistance taskforce. She has also been appointed to serve as a member on the annual scientific committee for non-prostate cancers.

Ken Westover, M.D., Ph.D., started his research career as a summer undergraduate research fellow in the labs of Nobel Prize laureates Michael Brown, M.D., and Joseph Goldstein, M.D., at UT Southwestern. It was there that he learned the basics of biochemistry and became convinced that he wanted to become a physician-scientist. 
After graduating with honors from Brigham Young University, with a B.S. in biochemistry, Dr. Westover entered the Stanford University Medical Scientist Training Program where he worked in the lab of Roger Kornberg, Ph.D., on the structural biology and biochemistry of gene transcription. Dr. Westover’s work was subsequently cited in the 2006 Nobel Prize for Chemistry awarded to Dr. Kornberg.
Radiation oncology was a natural fit for Dr. Westover given his laboratory experience, which had natural connections to cancer biology and included elements of imaging research, radiation science, and computer science. Most importantly, Dr. Westover found he was passionate about the practice of oncology. 
Dr. Westover completed his residency in radiation oncology at the Harvard Radiation Oncology Program, where he simultaneously worked in the lab of Nathanael Gray, Ph.D., in the Dana Farber Cancer Institute, learning principles of structure-based drug design and chemical biology. He also completed Harvard’s Intensive Translational Research Program.
Now at UT Southwestern, Dr. Westover focuses his clinical efforts on lung cancer and his research efforts on improving cancer therapies. In addition to targeted drug design, Dr. Westover hopes to find new ways to combine radiation therapy and targeted drugs.

Suzanne Cole, M.D., is a medical oncologist at UT Southwestern Medical Center. She serves as the Medical Director of the . She is also Medical Director of the Community Oncology Program at  and Research Leader for the Community Oncology Program.
Dr. Cole earned her medical degree at UT Southwestern, where she also completed her residency in internal medicine. She then received advanced training in hematology and medical oncology through a fellowship at the University of Texas MD Anderson Cancer Center in Houston.
Dr. Cole spent eight years caring for patients in their local communities before she joined the UT Southwestern faculty in 2018.
Board certified in hematology and oncology, Dr. Cole is a Fellow of the American College of Physicians. She is active in a number of cancer-related professional organizations, including the American Society of Clinical Oncology and the American Society of Hematology, and she previously served on the board of the Oklahoma Society of Clinical Oncology. She is the founder of the Hematology & Oncology Women Physician Group.
Dr. Cole has delivered presentations throughout the nation and published articles in peer-reviewed journals covering topics related to cancer and blood-related disorders.

David Gerber, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology/Oncology. He serves as Associate Director of Clinical Research for Simmons Cancer Center.
Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York, and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.  
Board certified in internal medicine and medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007. 
Dr. Gerber is active in research related to lung cancer, including clinical trials. His research has generated more than 250 publications that he has authored or co-authored, including articles and book chapters. His studies have contributed to invitations to lecture both nationally and internationally.
He serves on several committees at UT Southwestern. Beyond the institution, he serves as Chair of the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and is a member of the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee.
Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor in Dallas by D Magazine during the years of 2011-2023.

Medical Oncology Fellow at UTSW. Interested in lung cancer and immunotherapy research. 

Dr. Erminia Massarelli is a hematologist in Duarte, California and is affiliated with . She received her medical degree from University of Naples Faculty of Medicine and has been in practice for more than 20 years. Dr. Erminia Massarelli has expertise in treating lung cancer, breast cancer, prostate cancer, among other conditions - see all areas of . Dr. Erminia Massarelli accepts Medicare, Blue Cross, United Healthcare - see other .